15-30 c, stored in a dry place. In order to achieve the best absorption, the medicine should be taken immediately after meals, and the capsule must be swallowed whole. The clearance rate of this product from skin and nail tissue is slower than that from plasma. Therefore, for skin infections, the best clinical and mycological effects can be achieved within 2-4 weeks after drug withdrawal. For onychomycosis, the best clinical and mycological effects can be achieved within 6-9 months after drug withdrawal. For pregnancy type C, it is suggested that patients who have taken medicine for more than 1 month, and those who have anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine during treatment should have their liver function checked. If there is any abnormality, the medication should be stopped.

Patients with abnormal liver function should not take drugs unless the necessity of treatment exceeds the risk of liver injury. Itraconazole is mainly metabolized in the liver. The bioavailability of patients with liver cirrhosis decreased after taking the medicine. If necessary, it is suggested to monitor the plasma concentration of itraconazole and choose the appropriate dose. When neurological symptoms appear, the treatment should be terminated. For patients with renal insufficiency, the bioavailability of this drug may decrease. It is suggested to monitor the plasma concentration of this product to determine the appropriate dose.

People who are allergic to this medicine. It is forbidden for pregnant women, unless it is used for systemic fungal treatment, but the advantages and disadvantages should be weighed. Women of childbearing age should take appropriate contraceptive measures when using this product. Not suitable for lactating women. The impact on children is due to the limited clinical data of itraconazole used in children, so it is recommended not to use it in children unless the potential benefits outweigh the possible harm.